Advertisement

Reactions Weekly

, Volume 1738, Issue 1, pp 14–14 | Cite as

Alectinib

Acquired drug resistance with secondary ALK mutations: case report
Case report
  • 18 Downloads

Reference

  1. Kitadai R, et al. Ceritinib for an anaplastic lymphoma kinase rearrangement-positive patient previously treated with alectinib with poor performance status. OncoTargets and Therapy 12: 15-19, Jan 2019. Available from: URL: http://doi.org/10.2147/OTT.S186213 - JapanCrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Personalised recommendations